Kerlone

Glaucoma, Hypertensive disease, Ocular Hypertension + 2 more

Treatment

1 FDA approval

20 Active Studies for Kerlone

What is Kerlone

Betaxolol

The Generic name of this drug

Treatment Summary

A cardioselective beta-blocker medication that does not activate any of the beta receptors in the body.

Kerlone

is the brand name

Kerlone Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kerlone

Betaxolol

1989

19

Approved as Treatment by the FDA

Betaxolol, also known as Kerlone, is approved by the FDA for 1 uses such as Hypertensive disease .

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Effectiveness

How Kerlone Affects Patients

Betaxolol is a type of drug used to treat a range of conditions, including high blood pressure, abnormal heart rhythms, coronary heart disease, glaucoma, and heart failure. It works by blocking certain receptors that would usually increase the heart rate and blood pressure, as well as the amount of oxygen the heart needs. Betaxolol can also prevent the release of a hormone produced by the kidneys that causes the blood vessels to narrow. This drug does not have any stimulating effects or properties that help stabilize cell membranes.

How Kerlone works in the body

Betaxolol works by blocking the effects of catecholamines on certain receptors in the heart and blood vessels. This causes the heart rate to slow down, as well as reducing blood pressure both systoically and diastically. In some cases, it can also cause reflex orthostatic hypotension. It can also block beta(2)-adrenergic receptors in the bronchi and blood vessels, which can cause bronchospasm.

When to interrupt dosage

The amount of Kerlone is contingent upon the diagnosed state, including Glaucoma, Open-Angle, Increased Intra Ocular Pressure (IOP) and Betoptic. The measure of dosage is contingent upon the technique of delivery (e.g. Kit or Tablet, coated) featured in the chart below.

Condition

Dosage

Administration

Glaucoma

, 10.0 mg, 20.0 mg, 5.0 mg/mL, 5.6 mg/mL, 0.5 %, 0.25 %, 2.8 mg/mL, 2.5 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension, Suspension - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Kit, Solution, Solution - Ophthalmic, Kit - Ophthalmic

Hypertensive disease

, 10.0 mg, 20.0 mg, 5.0 mg/mL, 5.6 mg/mL, 0.5 %, 0.25 %, 2.8 mg/mL, 2.5 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension, Suspension - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Kit, Solution, Solution - Ophthalmic, Kit - Ophthalmic

Ocular Hypertension

, 10.0 mg, 20.0 mg, 5.0 mg/mL, 5.6 mg/mL, 0.5 %, 0.25 %, 2.8 mg/mL, 2.5 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension, Suspension - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Kit, Solution, Solution - Ophthalmic, Kit - Ophthalmic

Glaucoma, Open-Angle

, 10.0 mg, 20.0 mg, 5.0 mg/mL, 5.6 mg/mL, 0.5 %, 0.25 %, 2.8 mg/mL, 2.5 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension, Suspension - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Kit, Solution, Solution - Ophthalmic, Kit - Ophthalmic

Betoptic

, 10.0 mg, 20.0 mg, 5.0 mg/mL, 5.6 mg/mL, 0.5 %, 0.25 %, 2.8 mg/mL, 2.5 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Solution / drops - Ophthalmic, Solution / drops, Tablet, film coated, Tablet, film coated - Oral, Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension, Suspension - Ophthalmic, Suspension / drops - Ophthalmic, Suspension / drops, Kit, Solution, Solution - Ophthalmic, Kit - Ophthalmic

Warnings

There are 20 known major drug interactions with Kerlone.

Common Kerlone Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Betaxolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Betaxolol.

Abediterol

Major

The therapeutic efficacy of Abediterol can be decreased when used in combination with Betaxolol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Betaxolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Betaxolol.

Kerlone Toxicity & Overdose Risk

The toxic level of betaxolol in mice is between 350-400mg/kg and 860-980mg/kg in rats. Signs of overdose include slow heartbeat, congestive heart failure, low blood pressure, asthma attacks, and low blood sugar levels.

image of a doctor in a lab doing drug, clinical research

Kerlone Novel Uses: Which Conditions Have a Clinical Trial Featuring Kerlone?

49 active investigations are assessing the potential of Kerlone to reduce Increased Intra Ocular Pressure (IOP) and to serve as a treatment for Betoptic and Hypertensive disease.

Condition

Clinical Trials

Trial Phases

Ocular Hypertension

12 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Phase 4

Glaucoma

0 Actively Recruiting

Glaucoma, Open-Angle

39 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Betoptic

0 Actively Recruiting

Hypertensive disease

30 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Kerlone Reviews: What are patients saying about Kerlone?

5

Patient Review

1/22/2009

Kerlone for High Blood Pressure

Kerlone has really helped me manage my MVP over the years. The only downside is that I need such a small dose (5mg) that I have to cut the pills in half.

5

Patient Review

12/26/2009

Kerlone for High Blood Pressure

I'd been taking this medicine for around 15 years with great results, but then I was informed by Medco that it had been recalled and was no longer available. When I called Rite Aid to double check, they confirmed the recall. No reason was given by either company.

5

Patient Review

5/26/2010

Kerlone for High Blood Pressure

I've been taking this medication for 15 years to help manage my blood pressure. It's been working great, and I only need to take a small dose (5 mg)

5

Patient Review

10/12/2007

Kerlone for High Blood Pressure

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kerlone

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is kerlone discontinued?

"The drug Kerlone, which is used to treat hypertension, has been discontinued in the United States. However, generic forms of the drug may still be available."

Answered by AI

What is kerlone used for?

"This medication is used to treat high blood pressure. lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Betaxolol belongs to a class of drugs known as beta blockers."

Answered by AI

Is kerlone a beta adrenergic blocking agent?

"Kerlone is a β1-selective (cardioselective) adrenergic receptor blocking agent that mainly acts to stabilize membranes and has no intrinsic sympathomimetic (partial agonist) activity."

Answered by AI

What is betaxolol hydrochloride used for?

"This medicine is used to treat increased pressure in the eye that is caused by open-angle glaucoma or a condition called ocular (eye) hypertension."

Answered by AI

Clinical Trials for Kerlone

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Have you considered Kerlone clinical trials?

We made a collection of clinical trials featuring Kerlone, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Kerlone clinical trials?

We made a collection of clinical trials featuring Kerlone, we think they might fit your search criteria.
Go to Trials
Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL

This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.

Waitlist Available
Has No Placebo

U Health (+1 Sites)

Ziad Zoghby, M.D., M.B.A.

Biobeat Technologies Ltd.

Have you considered Kerlone clinical trials?

We made a collection of clinical trials featuring Kerlone, we think they might fit your search criteria.
Go to Trials